文献速递睡眠呼吸障碍

局部钾通道阻断改善咽部塌陷性:一项转化性安慰剂对照试验

Topical Potassium Channel Blockage Improves Pharyngeal Collapsibility: A Translational, Placebo-Controlled Trial.
PubMed 文献 · Chest · 2022-11-24

该研究在麻醉猪和OSA患者中评估TASK1/3通道拮抗剂BAY2586116对咽部塌陷性的影响。猪实验中3 μg和30 μg剂量持续改善负压下的咽部塌陷性;OSA患者中BAY2586116较安慰剂平均改善咽部塌陷性约2 cm H2O(P < .008),且不受局部应用方式和剂量影响。

要点

  • BAY2586116局部应用可改善麻醉猪和OSA患者的咽部塌陷性。
  • OSA患者中咽部塌陷性平均改善约2 cm H2O(P < .008)。
  • 改善效果不受局部应用方式和剂量影响。

核心结论

  • 急性局部应用BAY2586116可改善麻醉猪和睡眠OSA患者的上气道塌陷性。

研究设计与样本

  • 临床前研究:13只麻醉猪接受安慰剂、0.3 μg、3 μg和30 μg BAY2586116鼻滴。
  • 临床研究:12例OSA患者采用双盲随机交叉设计,睡前接受BAY2586116 160 μg或安慰剂鼻喷。
  • 多数参与者还完成三次额外夜间访视:鼻滴160 μg、半剂量鼻喷80 μg和直接内镜应用160 μg。

主要发现

  • 猪实验中3 μg和30 μg BAY2586116较安慰剂持续改善负压下的咽部塌陷性。
  • OSA患者中BAY2586116较安慰剂平均改善咽部塌陷性约2 cm H2O(P < .008,混合模型)。
  • OSA患者的改善不受局部应用方法和剂量影响。

关键数值与推荐

  • OSA患者中BAY2586116较安慰剂改善咽部塌陷性约2 cm H2O(P < .008)。

临床怎么用

  • 这些生理学发现提示靶向钾通道机制治疗OSA具有治疗潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Potassium (K+) channel inhibition has been identified in animal models as a potential target to increase pharyngeal dilator muscle activity and to treat OSA. However, these findings have not yet been translated to humans. RESEARCH QUESTION: Does a novel, potent, tandem of P domains in a weak inward rectifying K+ channel (TWIK)-related acid-sensitive K+ (TASK) 1/3 channel antagonist, BAY2586116, improve pharyngeal collapsibility in pigs and humans, and secondarily, what is the optimal dose and method of topical application? STUDY DESIGN AND METHODS: In the preclinical study, pharyngeal muscle activity and upper-airway collapsibility via transient negative pressure application was quantified in 13 anesthetized pigs during administration of placebo, 0.3 μg, 3 μg, and 30 μg nasal drops of BAY2586116. In the clinical study, 12 people with OSA instrumented with polysomnography equipment, an epiglottic pressure catheter, pneumotachograph, and nasal mask to monitor sleep and breathing performed up to four detailed upper airway sleep physiology studies. Participants received BAY2586116 (160 μg) or placebo nasal spray before sleep via a double-masked, randomized, crossover design. Most participants also returned for three additional overnight visits: (1) nasal drops (160 μg), (2) half-dose nasal spray (80 μg), and (3) direct endoscopic application (160 μg). The upper-airway critical closing pressure (Pcrit) during sleep was quantified at each visit. RESULTS: Consistent and sustained improvements in pharyngeal collapsibility to negative pressure were found with 3 and 30 μg of BAY2586116 vs placebo in pigs. Similarly, BAY2586116 improved pharyngeal collapsibility by an average of approximately 2 cm H2O vs placebo, regardless of topical application method and dose (P < .008, mixed model) in participants with OSA. INTERPRETATION: Acute topical application of BAY2586116 improves upper-airway collapsibility in anesthetized pigs and sleeping humans with OSA. These novel physiologic findings highlight the therapeutic potential to target potassium channel mechanisms to treat OSA. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT04236440; URL: www. CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Osman AM, Mukherjee S, Altree TJ, et al. Topical Potassium Channel Blockage Improves Pharyngeal Collapsibility: A Translational, Placebo-Controlled Trial. Chest. 2022. PMID: 36435266. doi:10.1016/j.chest.2022.11.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。